Skip to content

Strategic Sourcing

Analysis

Cosette Appoints Andrew Adams as VP, Supply Chain & Sourcing

Cosette has appointed Andrew Adams as Vice President of Supply Chain & Sourcing, effective September 10, 2026. The announcement appeared alongside other leadership moves reported by PharmaLive that same day, including appointments at EVERSANA and GBI Bio. PharmaLive’s historical coverage of pharmaceutical supply chain topics dates back to March 9, 2011, and includes analyses of global contract manufacturing, drug delivery systems, and OTC market outlooks. The appointment reflects ongoing industry emphasis on sourcing strategy and operational resilience.

Original source: pharmalive.com

Cosette Appoints Andrew Adams as VP, Supply Chain & Sourcing

Ask SCI.AI about this story

According to pharmalive.com, Cosette has appointed Andrew Adams as Vice President of Supply Chain & Sourcing.

Leadership Appointment Confirmed

The appointment was announced on September 10, 2026, at 9:42 am. This executive move follows a series of leadership updates reported by PharmaLive on the same date, including EVERSANA naming Stuart Diamond chief financial officer at 8:00 am and GBI Bio appointing Jesse McCool, Ph.D., as CEO at 8:50 am.

Andrew Adams joins Cosette amid heightened industry focus on supply chain resilience and strategic sourcing. His role directly supports Cosette’s operational infrastructure for pharmaceutical products, aligning with broader sector priorities highlighted across multiple PharmaLive reports dating back to March 9, 2011 and November 11, 2011.

The announcement appears in the context of ongoing coverage of pharmaceutical supply chain dynamics, including regional launch strategies influenced by Most Favored Nation (MFN) policy considerations reported on September 10, 2026 at 9:31 am.

Contextual Industry Reporting

PharmaLive’s coverage spans over a decade, with documented reports on global contract manufacturing published as early as November 11, 2011, and drug delivery analysis dated December 11, 2011. The outlet also tracks long-term trends such as OTC market review and outlook, first covered on March 9, 2011.

A recurring theme across these reports is the interdependence of regulatory compliance, clinical trial logistics, and end-to-end supply chain visibility — all areas falling under Adams’ new remit. The Cosette appointment coincides with industry-wide attention to manufacturing footprints, as seen in related coverage of AbbVie, AstraZeneca, and Bristol-Myers Squibb.

PharmaLive describes itself as the pharma industry’s destination for news and analysis, serving pharmaceutical and healthcare advertising and marketing professionals. Its reporting includes segments on drug pricing, patient access, and FDA regulatory approval processes — domains where supply chain integrity directly impacts outcomes.

Source: pharmalive.com

Compiled from international media by the SCI.AI editorial team.

Ask SCI.AI Finished reading? Continue with SCI.AI. Explore the related policy, route, company and historical context. Continue asking
Stay ahead of supply chain shifts

One email a week: the stories that matter and new risk events — in English, free.

Prefer RSS? Articles Risk events

Yangzijiang books $7B in orders, lifting backlog to $26.3B
Strategic Sourcing

Yangzijiang books $7B in orders, lifting backlog to $26.3B

Yangzijiang Shipbuilding has won almost US$7 billion in orders so far this year, lifting its outstanding order book to US$26.3 billion and beating its US$4.5 billion full-year target for FY2026. The contracts cover 87 vessels, including 53 container ships, 18 oil tankers and 13 bulk carriers. Container ships dominate the backlog at 173 vessels worth US$19.4 billion. The group has delivered 47 vessels, or 81 per cent of its 58-vessel FY2026 target, and its shares closed 5.5 per cent higher at S$4.59.

GXO contract wins jump 34% as pipeline hits $3.1B
Strategic Sourcing

GXO contract wins jump 34% as pipeline hits $3.1B

GXO Logistics booked $375 million in new business wins in the third quarter, up 34% year over year, lifting its sales pipeline to a record $3.1 billion. Revenue rose 5.7% to $3.59 billion and adjusted EPS climbed 13% to 89 cents, but rapid onboarding of large customers pushed up implementation costs, leaving adjusted EBITDA flat at $251 million and the margin at 7%. North America's pipeline jumped more than 80% to about $1.3 billion, while technology and consumer electronics revenue grew 19% on data center demand. GXO reaffirmed its 2026 guidance even as free cash flow fell 54.5% to $85 million.

Wallenius Wilhelmsen inks $1bn equipment manufacturing contracts
Strategic Sourcing

Wallenius Wilhelmsen inks $1bn equipment manufacturing contracts

Wallenius Wilhelmsen has secured two contracts worth more than $1bn with a major equipment manufacturer, covering ocean transportation and logistics services over three years. The shipping portion accounts for around $950m and the logistics business close to $100m, though the customer was not identified. The deal follows a $420m early extension with a European carmaker in June, a $190m distribution renewal in March and a $130m agreement in January. It also comes a day after the group ordered four 9,900 ceu LNG dual-fuel vessels at Jinling Shipyard, with options for eight more.

Welcome Back!

Login to your account below

Create New Account!

Fill the forms below to register

Retrieve your password

Please enter your username or email address to reset your password.

Scan to share via WeChat

Open WeChat and scan the QR code to share

QR Code

Add New Playlist